Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis.

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD) of the gastrointestinal tract. This study used non-invasive LC-MS/MS to find disease specific microbial and human proteins which might be used later for an easier diagnosis. Therefore, 17 healthy controls, 11 CD patients and 14 UC patients but also 13 Irritable Bowel Disease (IBS) patients, 8 Colon Adenoma (CA) patients, and 8 Gastric Carcinoma (GCA) patients were investigated. The proteins were extracted from the fecal samples with liquid phenol in a ball mill. Subsequently, the proteins were digested tryptically to peptides and analyzed by an Orbitrap LC-MS/MS. For protein identification and interpretation of taxonomic and functional results, the MetaProteomeAnalyzer software was used. Cluster analysis and non-parametric test (analysis of similarities) separated healthy controls from patients with CD and UC as well as from patients with GCA. Among others, CD and UC correlated with an increase of neutrophil extracellular traps and immune globulins G (IgG). In addition, a decrease of human IgA and the transcriptional regulatory protein RprY from Bacillus fragilis was found for CD and UC. A specific marker in feces for CD was an increased amount of the human enzyme sucrose-isomaltase. SIGNIFICANCE: Crohn's Disease and Ulcerative Colitis are chronic inflammatory diseases of the gastrointestinal tract, whose diagnosis required comprehensive medical examinations including colonoscopy. The impact of the microbial communities in the gut on the pathogenesis of these diseases is poorly understood. Therefore, this study investigated the impact of gut microbiome on these diseases by a metaproteome approach, revealing several disease specific marker proteins. Overall, this indicated that fecal metaproteomics has the potential to be useful as non-invasive tool for a better and easier diagnosis of both diseases.

[1]  Patrice D Cani.  Human gut microbiome: hopes, threats and promises , 2018, Gut.

[2]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[3]  E. Bellei,et al.  High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins , 2010, Amino Acids.

[4]  R. Knight,et al.  Evaluating Metagenomic Prediction of the Metaproteome in a 4.5-Year Study of a Patient with Crohn's Disease , 2019, mSystems.

[5]  Cynthia L. Sears,et al.  Bacteroides fragilis Enterotoxin Induces Intestinal Epithelial Cell Secretion of Interleukin-8 through Mitogen-Activated Protein Kinases and a Tyrosine Kinase-Regulated Nuclear Factor-κB Pathway , 2004, Infection and Immunity.

[6]  L. Chiarelli,et al.  Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase , 2012 .

[7]  Brandi L. Cantarel,et al.  Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn's Disease , 2012, PloS one.

[8]  A. Kostic,et al.  The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.

[9]  S. Bryant,et al.  Open mass spectrometry search algorithm. , 2004, Journal of proteome research.

[10]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[11]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[12]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[13]  R. Sherwood,et al.  Fecal calprotectin in inflammatory bowel disease , 2016, Clinical and experimental gastroenterology.

[14]  K. R. Clarke,et al.  Non‐parametric multivariate analyses of changes in community structure , 1993 .

[15]  Matthias Mann,et al.  Parallel Accumulation-Serial Fragmentation (PASEF): Multiplying Sequencing Speed and Sensitivity by Synchronized Scans in a Trapped Ion Mobility Device. , 2015, Journal of proteome research.

[16]  Philippe Marteau,et al.  Specificities of the fecal microbiota in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[17]  U Reichl,et al.  Sample prefractionation with liquid isoelectric focusing enables in depth microbial metaproteome analysis of mesophilic and thermophilic biogas plants. , 2014, Anaerobe.

[18]  L. Hao,et al.  Phosphotidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease , 2015, Thrombosis and Haemostasis.

[19]  S. Grivennikov,et al.  Microbiome, Inflammation, and Cancer , 2014, Cancer journal.

[20]  Amos Bairoch,et al.  The ENZYME database in 2000 , 2000, Nucleic Acids Res..

[21]  Beatriz Carvalho,et al.  Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening , 2017, Annals of Internal Medicine.

[22]  N Popov,et al.  [Reliable micromethod for determination of the protein content in tissue homogenates]. , 1975, Acta biologica et medica Germanica.

[23]  M. Vatn,et al.  Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD , 2015, Alimentary pharmacology & therapeutics.

[24]  K. Mimori,et al.  A tumor-suppressive role for trypsin in human cancer progression. , 2003, Cancer research.

[25]  J. Kao,et al.  Intestinal dysbiosis in inflammatory bowel disease , 2011, Gut microbes.

[26]  Octávio L. Franco,et al.  Metaproteomics as a Complementary Approach to Gut Microbiota in Health and Disease , 2017, Front. Chem..

[27]  K. Isselbacher,et al.  Biogenesis of intestinal plasma membrane: posttranslational route and cleavage of sucrase-isomaltase. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Horwitz,et al.  Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn’s disease , 2000, Clinical and experimental immunology.

[29]  R. Heyer,et al.  Metaproteome analysis of the microbial communities in agricultural biogas plants. , 2013, New biotechnology.

[30]  Brandi L Cantarel,et al.  Metaproteomics reveals persistent and phylum-redundant metabolic functional stability in adult human gut microbiomes of Crohn’s remission patients despite temporal variations in microbial taxa, genomes, and proteomes , 2019, Microbiome.

[31]  Silvia Franchini,et al.  Cell-Cycle Inhibition by Helicobacter pylori L-Asparaginase , 2010, PloS one.

[32]  P. Malfertheiner,et al.  Validation of Two Calprotectin Rapid Tests in Daily Routine. , 2016, Clinical laboratory.

[33]  M. Bøgsted,et al.  Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies , 2015, Inflammatory bowel diseases.

[34]  R. Heyer,et al.  The MetaProteomeAnalyzer: a powerful open-source software suite for metaproteomics data analysis and interpretation. , 2015, Journal of proteome research.

[35]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[36]  Adam M. Phillippy,et al.  Interactive metagenomic visualization in a Web browser , 2011, BMC Bioinformatics.

[37]  Qiang Feng,et al.  Gut microbiome development along the colorectal adenoma–carcinoma sequence , 2015, Nature Communications.

[38]  C. Kolmeder,et al.  Metaproteomics of our microbiome - developing insight in function and activity in man and model systems. , 2014, Journal of proteomics.

[39]  A. Magee,et al.  Immunofluorescent localisation of enterokinase in human small intestine. , 1977, Gut.

[40]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. , 2018, Journal of Crohn's & colitis.

[41]  P. Gibbs,et al.  Use of multiple reaction monitoring for multiplex analysis of colorectal cancer‐associated proteins in human feces , 2011, Electrophoresis.

[42]  Y. Katayama.  Bowel disorders. , 1990, Postgraduate medicine.

[43]  J. Reimund,et al.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. , 1996, Gut.

[44]  R. Valenta,et al.  IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases , 2002, Clinical and experimental immunology.

[45]  A. Franco,et al.  The Bacteroides fragilis Toxin Binds to a Specific Intestinal Epithelial Cell Receptor , 2006, Infection and Immunity.

[46]  I. Forgacs,et al.  Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. , 1996, Gut.

[47]  F. Guarner,et al.  Gut flora in health and disease , 2003, The Lancet.

[48]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[49]  Alberto Mantovani,et al.  Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.

[50]  Surajit Pathak,et al.  Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature? , 2012, Expert review of clinical immunology.

[51]  C. Lees,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2011, Gut.

[52]  Maria Jesus Martin,et al.  UniProtJAPI: a remote API for accessing UniProt data , 2008, Bioinform..

[53]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[54]  C. Morrow,et al.  Gastric Microbiome and Gastric Cancer , 2014, Cancer journal.

[55]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[56]  Cheng-Fu Xu,et al.  Olfactomedin-4 in digestive diseases: A mini-review , 2018, World journal of gastroenterology.

[57]  R. Milo,et al.  Revised Estimates for the Number of Human and Bacteria Cells in the Body , 2016, bioRxiv.

[58]  N. Pace,et al.  Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. , 2008, Cell host & microbe.

[59]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..

[60]  A. Heintz‐Buschart,et al.  Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes , 2016, Nature Microbiology.

[61]  R. Heyer,et al.  Proteotyping of biogas plant microbiomes separates biogas plants according to process temperature and reactor type , 2016, Biotechnology for Biofuels.

[62]  N. Mantis,et al.  Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut , 2011, Mucosal Immunology.

[63]  Peter B. McGarvey,et al.  UniRef: comprehensive and non-redundant UniProt reference clusters , 2007, Bioinform..

[64]  M. Piazuelo,et al.  Helicobacter pylori Infection and Gastric Adenocarcinoma. , 2011, US gastroenterology & hepatology review.

[65]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[66]  Scott Federhen,et al.  The NCBI Taxonomy database , 2011, Nucleic Acids Res..

[67]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.